

Thomas Buttgereit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6887992/publications.pdf>

Version: 2024-02-01

12
papers

178
citations

1307594

7
h-index

1281871

11
g-index

13
all docs

13
docs citations

13
times ranked

314
citing authors

#	ARTICLE	IF	CITATIONS
1	How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 113-124.	3.8	46
2	Definition, aims, and implementation of GA ² /LEN/HAEi Angioedema Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2115-2123.	5.7	29
3	The Diagnostic Workup in Chronic Spontaneous Urticaria—What to Test and Why. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2274-2283.	3.8	21
4	Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1747-1754.	2.4	20
5	Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3744-3751.	3.8	17
6	SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. <i>RMD Open</i> , 2022, 8, e001934.	3.8	16
7	Idiopathic mast cell activation syndrome is more often suspected than diagnosed—A prospective real-life study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2794-2802.	5.7	12
8	Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 1171-1172.	0.8	4
9	Treatment of severe heat urticaria with omalizumab — report of a case and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e489-e491.	2.4	3
10	Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab. <i>JAAD Case Reports</i> , 2021, 15, 36-38.	0.8	3
11	POS0183—SIGLEC1 AS A TYPE I INTERFERON BIOMARKER IN IDIOPATHIC INFLAMMATORY MYOPATHIES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 305.1-305.	0.9	0
12	SAT0372—PATIENTS WITH PSORIATIC ARTHRITIS SHOW HIGHER BONE DENSITY COMPARED TO AGE AND GENDER MATCHED PATIENTS WITH ANKYLOSING SPONDYLITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1133.2-1134.	0.9	0